Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 18,411 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Terminated Not applicable Interventional Results available

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

NCT01275664
View directory record Official record
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 30, 2026, 12:03 PM EDT
Active, not recruiting Phase 1 Interventional

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

NCT04794699
View directory record Official record
Conditions
Solid Tumor
Interventions
IDE397, Sacituzumab govitecan
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence

NCT00345332
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Botox, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
3
States / cities
Sacramento, California • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 30, 2026, 12:03 PM EDT
Completed No phase listed Observational

Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients

NCT00153621
View directory record Official record
Conditions
Chronic Kidney Failure, AIDS-Associated Nephropathy, HIV Infections
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 2 Interventional

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

NCT00034021
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions
Ginkgo Biloba, Sex Therapy (genital focus)
Drug · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

NCT00598806
View directory record Official record
Conditions
Bladder Cancer
Interventions
Apaziquone, Placebo, TURBT
Drug · Procedure
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
21
States / cities
Anaheim, California • West Palm Beach, Florida • Marietta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting No phase listed Observational

Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy

NCT07214584
View directory record Official record
Conditions
Cervical Cancer, Human Papilloma Virus (HPV)
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting Phase 2 Interventional

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Completed No phase listed Observational Results available

Flexiva Pulse Registry

NCT05027971
View directory record Official record
Conditions
Urinary Calculi, Benign Prostatic Hyperplasia
Interventions
Flexiva Pulse High Power Single-Use Laser Fibers
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 30, 2026, 12:03 PM EDT
Terminated Phase 2 Interventional Results available

Mechanisms of EPO-induced Hypertension

NCT03810911
View directory record Official record
Conditions
Chronic Kidney Disease, Blood Pressure, Anemia
Interventions
Darbepoetin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Chronic Kidney Disease Antidepressant Sertraline Trial

NCT00946998
View directory record Official record
Conditions
Chronic Kidney Disease, Depression
Interventions
Sertraline, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Not applicable Interventional

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

NCT00287898
View directory record Official record
Conditions
Breast Cancer
Interventions
Telephone Genetic Counseling, Usual Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 3 Interventional

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

NCT00022087
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium salts, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
40 Years and older · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
107
States / cities
Arroyo Grande, California • La Jolla, California • Mountain View, California + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 30, 2026, 12:03 PM EDT
Active, not recruiting No phase listed Observational

Feasibility of Radiation-Free Percutaneus Nephrolithotomy for Kidney Stones

NCT06922006
View directory record Official record
Conditions
Kidney Stones
Interventions
Percutaneus nephrolithotomy (PCNL)
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 30, 2026, 12:03 PM EDT
Not listed Not applicable Interventional

Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.

NCT06097234
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Floor Disorders
Interventions
Pelex Upp, Pelvic Floor Physical Therapy
Device · Behavioral
Lead sponsor
Pelex
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Little Neck, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

NCT05045144
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 30, 2026, 12:03 PM EDT
Completed No phase listed Observational

The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery

NCT02496234
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Sapere Bio
Industry
Eligibility
50 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 30, 2026, 12:03 PM EDT
Completed No phase listed Observational

Prenatal Depression Prevention Effects on Parenting and Young Child Self-Regulation and Functioning

NCT04296734
View directory record Official record
Conditions
Postpartum Depression, Child Development, Parenting, Child Self-Regulation
Interventions
Mothers and Babies
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Months and older
Enrollment
960 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

NCT02942004
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

NCT00085358
View directory record Official record
Conditions
Brenner Tumor, Fallopian Tube Cancer, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
carboplatin, paclitaxel, docetaxel, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
16
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Not applicable Interventional

Screening Mammography and Latinas: A Multilevel Intervention

NCT02010008
View directory record Official record
Conditions
Breast Cancer
Interventions
Motivational Interviewing Intervention
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 30, 2026, 12:03 PM EDT
Active, not recruiting Not applicable Interventional

INTIBIA Pivotal Study

NCT05250908
View directory record Official record
Conditions
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
Interventions
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
22 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 12:03 PM EDT